We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+8.9%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$125M
Cap. Flow
+$100M
Cap. Flow %
7.26%
Top 10 Hldgs %
41.14%
Holding
237
New
73
Increased
38
Reduced
39
Closed
63

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$12.5M
2
ETNB
89bio
ETNB
+$10.8M
3
IMTX icon
Immatics
IMTX
+$6.72M
4
BMY icon
Bristol-Myers Squibb
BMY
+$6.02M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$5.91M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$15.7M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$12.5M
3
KURA icon
Kura Oncology
KURA
+$10.1M
4
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$9.46M
5
ZGNX
Zogenix, Inc.
ZGNX
+$7.96M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NERV icon
201
PUT
Minerva Neurosciences
NERV
$185M
– –
-43,288
Closed -$1.25M
OHI icon
202
PUT
Omega Healthcare
OHI
$15.1B
– –
-500,000
Closed -$14.9M
QQQ icon
203
CALL
Invesco QQQ Trust
QQQ
$453B
– –
-125,000
Closed -$30.9M
RARE icon
204
CALL
Ultragenyx Pharmaceutical
RARE
$2.45B
– –
-73,500
Closed -$5.75M
RARE icon
205
Ultragenyx Pharmaceutical
RARE
$2.45B
– –
-2,313
Closed -$181K
SLNO
206
CALL
DELISTED
Soleno Therapeutics
SLNO
– –
-70,000
Closed -$2.33M
SLNO
207
DELISTED
Soleno Therapeutics
SLNO
– –
-22,453
Closed -$748K
SLNO
208
PUT
DELISTED
Soleno Therapeutics
SLNO
– –
-78,587
Closed -$2.62M
SNDX icon
209
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-16,000
Closed -$237K
VKTX icon
210
Viking Therapeutics
VKTX
$3.7B
– –
-1,159
Closed -$8K
VNQ icon
211
PUT
Vanguard Real Estate ETF
VNQ
$39.2B
– –
-250,000
Closed -$19.6M
XLE icon
212
PUT
State Street Energy Select Sector SPDR ETF
XLE
$39.6B
– –
-486,200
Closed -$9.2M
XLF icon
213
PUT
State Street Financial Select Sector SPDR ETF
XLF
$56.7B
– –
-600,000
Closed -$13.9M
CSCI
214
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
– –
-1,174
Closed -$94K
VIRX
215
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-3,184
Closed -$29K
CBAY
216
DELISTED
Cymabay Therapeutics
CBAY
– –
-1,529,830
Closed -$5.34M
ICPT
217
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-150,000
Closed -$7.19M
ICPT
218
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-35,500
Closed -$1.7M
ZYNE
219
CALL
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-961,400
Closed -$3.24M
ZYNE
220
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-647,400
Closed -$2.18M
ZYNE
221
PUT
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-692,500
Closed -$2.33M
KDNY
222
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-673,995
Closed -$7.79M
STSA
223
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
– –
-328,824
Closed -$9.46M
OBSV
224
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-82,573
Closed -$486K
MYOV
225
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-25,999
Closed -$484K
6 7 8
9
10

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Ikarian Capital held 237 positions worth $1.38B, up 10% from $1.26B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ikarian Capital deployed $100M of net new capital in Q3 2020, opening 73 new positions and adding to 38 existing holdings. Its largest new stake was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 25% a quarter earlier.

On the sell side, the largest reduction was BioXcel Therapeutics, an estimated $12.5M trimmed.

  • Ikarian Capital's largest Q3 2020 buy was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.
  • Ikarian Capital added most to Kiniksa Pharmaceuticals in Q3 2020, an estimated $5.91M increase.
  • Ikarian Capital's biggest Q3 2020 reduction was BioXcel Therapeutics, cutting an estimated $12.5M.
  • Ikarian Capital fully exited Blueprint Medicines in Q3 2020, selling an estimated $15.7M.
  • Ikarian Capital's ten largest holdings make up 41% of its $1.38B portfolio in Q3 2020.
  • Ikarian Capital opened 73 new positions and closed 63 in Q3 2020.
  • Ikarian Capital's portfolio value rose 10% quarter-over-quarter to $1.38B.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.